We found for
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
![The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe](https://www.ohe.org/wp-content/uploads/2023/06/NGS-report_AdobeStock_406823942_portrait.jpg)
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
![Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies](https://www.ohe.org/wp-content/uploads/2023/01/Cancer_WellcomeCollection_landscape.jpg)
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
![Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies](https://www.ohe.org/wp-content/uploads/2020/08/Bridge-150x150.png)